AR104735A1 - Terapia combinada de un anticuerpo anti-cd20 con un inhibidor de bcl-2 y un inhibidor de mdm2, método de tratamiento, uso - Google Patents

Terapia combinada de un anticuerpo anti-cd20 con un inhibidor de bcl-2 y un inhibidor de mdm2, método de tratamiento, uso

Info

Publication number
AR104735A1
AR104735A1 ARP160101500A ARP160101500A AR104735A1 AR 104735 A1 AR104735 A1 AR 104735A1 AR P160101500 A ARP160101500 A AR P160101500A AR P160101500 A ARP160101500 A AR P160101500A AR 104735 A1 AR104735 A1 AR 104735A1
Authority
AR
Argentina
Prior art keywords
antibody
inhibitor
bcl
phenyl
sulfonyl
Prior art date
Application number
ARP160101500A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR104735A1 publication Critical patent/AR104735A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

Terapia combinada de un anticuerpo anti-CD20 con un inhibidor de Bcl-2 y un inhibidor de MDM2 para el tratamiento del cáncer, especialmente a la terapia combinada de cánceres que expresan CD20 con un anticuerpo anti-CD20 de tipo 1 o un anticuerpo B-Ly1 humanizado no fucosilado y un inhibidor de Bcl-2 y un inhibidor de MDM2. Reivindicación 1: Un anticuerpo anti-CD20 para el tratamiento del cáncer en combinación con un inhibidor de Bcl-2 y un inhibidor de MDM2. Reivindicación 5: El anticuerpo de acuerdo con una cualquiera de las reivindicaciones 1 a 4, caracterizado por que dicho anticuerpo anti-CD20 no fucosilado es un anticuerpo B-Ly1 humanizado. Reivindicación 6: El anticuerpo de acuerdo con una cualquiera de las reivindicaciones 1 a 5, caracterizado por que dicho anticuerpo anti-CD20 no fucosilado es obinutuzumab. Reivindicación 7: El anticuerpo de acuerdo con una cualquiera de las reivindicaciones 1 a 5, caracterizado por que dicho anticuerpo anti-CD20 de tipo I es rituximab. Reivindicación 8: El anticuerpo de acuerdo con una cualquiera de las reivindicaciones 1 a 7, caracterizado por que el inhibidor de Bcl-2 es 4-(4-{[2-(4-clorofenil)-4,4-dimetilciclohex-1-en-1-il]metil}piperazin-1-il)-2-(1H-pirrolo[2,3-b]piridin-5-iloxi)-N-({4-[(tetrahidro-2H-piran-4-ilmetil)amino]-3-[(trifluorometil)sulfonil]fenil}sulfonil)benzamida. Reivindicación 9: El anticuerpo de acuerdo con una cualquiera de las reivindicaciones 1 a 7, caracterizado por que el inhibidor de MDM2 es ácido 4-{[(2R,3S,4R,5S)-4-(4-cloro-2-fluoro-fenil)-3-(3-cloro-2-fluoro-fenil)-4-ciano-5-(2,2-dimetil-propil)-pirrolidin-2-carbonil]-amino}-3-metoxibienzoico. Reivindicación 11: Una composición farmacéutica que comprende una combinación de un anticuerpo anti-CD20 de tipo I o un anticuerpo B-Ly1 humanizado que está sin fucosilar con una cantidad de fucosa del 60% o menos de la cantidad total de oligosacáridos (azúcares) en Asn297, y 4-(4-{[2-(4-clorofenil)-4,4-dimetilciclohex-1-en-1-il]metil}piperazin-1-il)-2-(1H-pirrolo[2,3-b]piridin-5-iloxi)-N-({4-[(tetrahidro-2H-piran-4-ilmetil)amino]-3-[(trifluorometil)sulfonil]fenil}sulfonil)benzamida y ácido 4-{[(2R,3S,4R,5S)-4-(4-cloro-2-fluoro-fenil)-3-(3-cloro-2-fluoro-fenil)-4-ciano-5-(2,2-dimetil-propil)-pirrolidin-2-carbonil]-amino}-3-metoxibenzoico o una sal de los mismos para el tratamiento del cáncer.
ARP160101500A 2015-05-26 2016-05-24 Terapia combinada de un anticuerpo anti-cd20 con un inhibidor de bcl-2 y un inhibidor de mdm2, método de tratamiento, uso AR104735A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15169199 2015-05-26

Publications (1)

Publication Number Publication Date
AR104735A1 true AR104735A1 (es) 2017-08-09

Family

ID=53264535

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160101500A AR104735A1 (es) 2015-05-26 2016-05-24 Terapia combinada de un anticuerpo anti-cd20 con un inhibidor de bcl-2 y un inhibidor de mdm2, método de tratamiento, uso

Country Status (31)

Country Link
US (1) US20160347852A1 (es)
EP (1) EP3302549B1 (es)
JP (1) JP6612362B2 (es)
KR (1) KR102043803B1 (es)
CN (1) CN107847600B (es)
AR (1) AR104735A1 (es)
AU (1) AU2016267564B2 (es)
BR (1) BR112017023517A2 (es)
CA (1) CA2984706A1 (es)
CL (1) CL2017002983A1 (es)
CR (1) CR20170529A (es)
DK (1) DK3302549T3 (es)
ES (1) ES2744624T3 (es)
HK (1) HK1252855A1 (es)
HR (1) HRP20191585T1 (es)
HU (1) HUE044853T2 (es)
IL (1) IL255353B (es)
LT (1) LT3302549T (es)
MA (1) MA44645B1 (es)
MX (1) MX2017014977A (es)
MY (1) MY188849A (es)
NZ (1) NZ736727A (es)
PE (1) PE20180454A1 (es)
PL (1) PL3302549T3 (es)
PT (1) PT3302549T (es)
RS (1) RS59204B1 (es)
RU (1) RU2727196C2 (es)
SI (1) SI3302549T1 (es)
UA (1) UA124617C2 (es)
WO (1) WO2016188935A1 (es)
ZA (1) ZA201707357B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3919079A1 (en) 2012-09-07 2021-12-08 Genentech, Inc. Combination therapy of a type ii anti-cd20 antibody with a selective bcl-2 inhibitor
WO2018106931A1 (en) 2016-12-07 2018-06-14 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
EP4108183A1 (en) 2017-03-30 2022-12-28 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
US20210106703A1 (en) * 2017-11-22 2021-04-15 Nordic Nanovector Asa Radioimmunoconjugates in combination with other drugs as treatment against nhl
NZ765825A (en) 2018-01-10 2023-12-22 Recurium Ip Holdings Llc Benzamide compounds
US20230041197A1 (en) 2018-06-20 2023-02-09 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
WO2019246317A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease or condition in a tissue originating from the endoderm
TWI725488B (zh) 2018-07-31 2021-04-21 大陸商蘇州亞盛藥業有限公司 Bcl-2抑制劑與化療藥的組合產品及其在預防及/或治療疾病中的用途
WO2020024826A1 (en) * 2018-07-31 2020-02-06 Ascentage Pharma (Suzhou) Co., Ltd. Synergistic antitumor effect of bcl-2 inhibitor combined with rituximab and/or bendamustine or bcl-2 inhibitor combined with chop
WO2020106757A1 (en) 2018-11-19 2020-05-28 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
EP3870261B1 (en) 2019-12-13 2024-01-31 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090098118A1 (en) * 2007-10-15 2009-04-16 Thomas Friess Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agent
MX2013006739A (es) * 2010-12-16 2013-07-17 Roche Glycart Ag Terapia combinada de anticuerpo cd20 afucosilado con inhibidor de mdm2.

Also Published As

Publication number Publication date
AU2016267564A1 (en) 2017-11-16
DK3302549T3 (da) 2019-09-16
RU2017145649A3 (es) 2019-10-23
RU2727196C2 (ru) 2020-07-21
MY188849A (en) 2022-01-09
ZA201707357B (en) 2020-05-27
HK1252855A1 (zh) 2019-06-06
PT3302549T (pt) 2019-09-09
JP6612362B2 (ja) 2019-11-27
WO2016188935A1 (en) 2016-12-01
NZ736727A (en) 2022-09-30
KR102043803B1 (ko) 2019-11-12
RS59204B1 (sr) 2019-10-31
PE20180454A1 (es) 2018-03-05
LT3302549T (lt) 2019-09-25
CA2984706A1 (en) 2016-12-01
EP3302549A1 (en) 2018-04-11
US20160347852A1 (en) 2016-12-01
AU2016267564B2 (en) 2022-09-01
MA44645B1 (fr) 2019-09-30
CN107847600B (zh) 2021-09-03
JP2018515583A (ja) 2018-06-14
IL255353B (en) 2021-08-31
EP3302549B1 (en) 2019-07-03
HUE044853T2 (hu) 2019-11-28
SI3302549T1 (sl) 2019-10-30
CL2017002983A1 (es) 2018-05-04
PL3302549T3 (pl) 2019-11-29
RU2017145649A (ru) 2019-06-26
ES2744624T3 (es) 2020-02-25
MX2017014977A (es) 2018-03-23
HRP20191585T1 (hr) 2019-11-29
BR112017023517A2 (pt) 2018-07-24
IL255353A0 (en) 2017-12-31
CN107847600A (zh) 2018-03-27
CR20170529A (es) 2018-01-26
UA124617C2 (uk) 2021-10-20
KR20180004285A (ko) 2018-01-10

Similar Documents

Publication Publication Date Title
AR104735A1 (es) Terapia combinada de un anticuerpo anti-cd20 con un inhibidor de bcl-2 y un inhibidor de mdm2, método de tratamiento, uso
CL2020000122A1 (es) Métodos de tratamiento para la fibrosis quística.
PE20220253A1 (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
BR112017007460A2 (pt) inibidores de di-hidropirrolopiridina de ror-gama
UA122520C2 (uk) Кристалічна форма 2-[4-(4-хлорфенокси)-2-(трифторметил)феніл]-1-(1,2,4-триазол-1-іл)пропан-2-олу, агрохімічна композиція, застосування та спосіб боротьби зі шкідливими грибами
NI201700101A (es) Composiciones farmacéuticas que comprenden n - (3, 5 - dimetoxifenil) - n'- (1-metiletil) - n - [3-(1-metil-1h-pirazol-4-il) quinoxalina-6-il]etano-1,2-diamina
PE20191555A1 (es) Agentes inductores de la apoptosis para tratar el cancer y enfermedades inmunes y autoinmunes
MD3464265T2 (ro) Polimorfi de N-[(3-fluoro-4-metoxipiridin-2-il)metil]-3-(metoximetil)-1-({4-[2-oxopiridin-1-il)metil]fenil}metil)pirazol-4-carboxamidă ca inhibitori de kalicreină
BR112015029455A8 (pt) compostos químicos, uso, métodos e composições para prevenção ou tratamento de câncer
BR112013012740A2 (pt) sais e formas cristalinas de um agente que induz apoptose
EA201691242A1 (ru) Фармацевтические композиции, содержащие azd9291
PE20141824A1 (es) Compuestos terapeuticamente activos y sus metodos de uso
CY1121421T1 (el) Φαρμακοτεχνικες μορφες
BR112016028749A2 (pt) composto, forma cristalina, composição farmacêutica, e, método para o tratamento de uma doença.
BR112017004673A2 (pt) formas cristalinas de 2-(4-(4-etoxi-6-oxo-1,6-diidropiridin-3-ila)-2-fluorofenil)-n-(5-(1,1,1-trifluoro-2-metilpropan-2-il)isoxazol-3-il) acetamida
EA202092620A1 (ru) Соли и твердые формы монобактамного антибиотика
PE20161236A1 (es) Compuesto de triazina y su uso para fines medicos
BR112013029999A2 (pt) derivados de tiazol
BR112018073951A2 (pt) forma cristalina inovadora de n-[5-(3,5-difluoro-benzil)-1h-indazol-3-il]-4-(4-metil-piperazin-1-il)-2-(tetra-hidro-piran-4-ilamino)-benzamida
BR112018011851A2 (pt) compostos de isoindol
EA201692470A1 (ru) Фармацевтические комбинации
CL2019001628A1 (es) Combinación farmacéutica que comprende un bloqueador del canal de calcio de tipo t.
EA201692474A1 (ru) Производные 1-(циклопент-2-ен-1-ил)-3-(2-гидрокси-3-(арилсульфонил)фенил)мочевины в качестве ингибиторов cxcr2
EP4249513A3 (en) Combinations of a hdm2-p53 interaction inhibitor and a bcl2 inhibitor and their use for treating cancer
MX2022013566A (es) Anticuerpo.

Legal Events

Date Code Title Description
FB Suspension of granting procedure